NRIX Nurix Therapeutics Inc
Company Analysis
Latest News
General Atlantic Takes $93 Million Nurix Stake, Its 9th Largest Holding
General Atlantic L.P. purchased 4,897,159 shares of Nurix Therapeutics, Inc. The investment is valued at approximately $92.9 million. This acquisition gives...
🟢 Nurix Therapeutics Inc is trading 5.1% up today, extending gains on clinical trial progress and insider activity
Nurix Therapeutics Inc is trading at $17.94 (up 5.1%), extending gains from last week’s rally as momentum continues to build around the company's recent...
🟢 Nurix Therapeutics Inc makes sharp 11.1% jump
NRIX is trading at $18.86, up 11.1% versus the comparison close of $16.98 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 Nurix Therapeutics Inc is trading 5.1% up today as rally extends on 93% blood cancer drug response rate
Nurix Therapeutics Inc is trading 5.1% up today at $17.84, extending a sharp rally driven by breakthrough clinical data for its lead blood cancer treatment. •...
Nurix's Blood Cancer Drug Posts 93% Response Rate — But Can a $1.5 Billion Biotech Turn Promising Data Into Real Revenue?
Shares jumped 7.1% to $16.39 as Nurix Therapeutics unveiled updated trial results for its lead cancer drug at the European Hematology Association Congress in...
🟢 Nurix Therapeutics Inc makes sharp 10.2% jump
NRIX is trading at $16.86, up 10.2% versus the comparison close of $15.30 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 Nurix Therapeutics Inc is trading 7.1% up today after reporting high response rates in Phase 1 leukemia trial
Nurix Therapeutics Inc is trading at $16.39 (7.1% up) after releasing updated Phase 1a/1b data for its BTK degrader bexobrutideg (NX-5948) in relapsed or...
Nurix Reports Positive Phase 1 Trial Data for Bexobrutideg in Leukemia (CLL/SLL)
Nurix Therapeutics announced updated positive clinical data from its Phase 1a/1b study of bexobrutideg (NX-5948), a BTK degrader, in patients with relapsed or...